scispace - formally typeset
Open AccessJournal ArticleDOI

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

Reads0
Chats0
TLDR
Strong evidence now shows that people with RA are at a high risk for developing several comorbid disorders, that these conditions may have atypical features and thus may be difficult to diagnose, and that persons with RA experience poorer outcomes after comorbridity compared with the general population.
Abstract
Epidemiology is the study of the distribution and determinants of disease in human populations. Over the past decade there has been considerable progress in our understanding of the fundamental descriptive epidemiology (levels of disease frequency: incidence and prevalence, comorbidity, mortality, trends over time, geographic distributions, and clinical characteristics) of the rheumatic diseases. This progress is reviewed for the following major rheumatic diseases: rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, giant cell arteritis, polymyalgia rheumatica, gout, Sjogren's syndrome, and ankylosing spondylitis. These findings demonstrate the dynamic nature of the incidence and prevalence of these conditions – a reflection of the impact of genetic and environmental factors. The past decade has also brought new insights regarding the comorbidity associated with rheumatic diseases. Strong evidence now shows that persons with RA are at a high risk for developing several comorbid disorders, that these conditions may have atypical features and thus may be difficult to diagnose, and that persons with RA experience poorer outcomes after comorbidity compared with the general population. Taken together, these findings underscore the complexity of the rheumatic diseases and highlight the key role of epidemiological research in understanding these intriguing conditions.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis

TL;DR: Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage, and new agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.
Journal ArticleDOI

All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study.

TL;DR: Patients with osteoarthritis are at higher risk of death compared with the general population, and history of diabetes, cancer, or cardiovascular disease and the presence of walking disability are major risk factors.
Journal ArticleDOI

The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases

TL;DR: One in 12 women and 1 in 20 men will develop an inflammatory autoimmune rheumatic disease during their lifetime, which can serve as useful guides in counseling patients regarding their lifetime risk of these conditions and have important implications regarding disease awareness campaigns.
References
More filters
Journal ArticleDOI

Prediction of Coronary Heart Disease Using Risk Factor Categories

TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.

National Arthritis Data Work-group. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

TL;DR: In this paper, the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain are provided.
Journal ArticleDOI

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Related Papers (5)

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.